What are you searching for?

09.02.2022 | Tracker

Product Launch Tracker: HCPs celebrate new treatments for metastatic melanoma and non-small cell lung cancer

CREATION Team photo of Research Associate Paul Cranston By Paul Cranston and Tomi Shobande

Every month, CREATION.co’s tracking updates bring you the latest insights from the conversation of healthcare professionals (HCPs) across the globe discussing product launches. Discover which new drug approvals HCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in CREATION.co’s latest tracking update.

———

Throughout January 2022 we tracked the global conversations of 2,797 HCPs who posted 4,166 English-language Twitter posts about the launches and approvals of new products.

In January, HCPs conversation in relation to product approvals quietened slightly compared to the previous month, with two COVID-19 related approvals driving spikes in conversation at the beginning and end of the month. In smaller numbers, HCPs also shared the news of approvals of two treatments for non-small cell lung cancer (NSCLC), the EMA indication extension of Keytruda, and the first FDA approval of a treatment for metastatic uveal melanoma.

The ever-evolving landscape of COVID-19 vaccines shifted again on January 31, with Moderna winning full approval for its jab from the FDA. Moderna’s two-shot mRNA vaccine, now branded Spikevax, was previously being administered under emergency use authorisation.

Early this month, the FDA also authorised the use of a third ‘booster’ dose of the Pfizer and BioNTech COVID-19 vaccine for children ages 12 to 15 and narrowed the interval for a booster shot eligibility to five months from six. The agency also authorised a third shot for children aged 5 through 11 years who are immunocompromised. 

The final COVID-19 related authorisation that grabbed the attention of HCPs, was the FDA approval of remdesivir for the treatment of outpatients with mild-to-moderate COVID-19. HCPs took the chance to support the drug when members of the public shared critical opinions of it.

The FDA also approved Kimmtrak (tebentafusp-tebn) from Immunocore Ltd for adult patients with unresectable or metastatic uveal melanoma. HCPs reacted positively to the approval, highlighting its importance as 1st and only FDA approved therapy for the treatment of metastatic uveal melanoma”. 

Additionally, HCPs shared the news that the EMA had extended the indication for Merck’s Keytruda (pembrolizumab) with its approval as an adjuvant therapy for certain patients With renal cell carcinoma (RCC) at increased risk of recurrence. HCPs welcomed the approval and looked forward to having more options that could extend survival and quality of life for renal cancer patients.

Other HCPs also drew attention to two approvals in NSCLC this month. The first being Abbvie’s Teliso-V (telisotuzumab vedotin), which the FDA granted Breakthrough Therapy Designation (BTD) for previously treated NSCLC. The second being Pfizer’s Lorviqua (lorlatinib), which was approved in the EU for first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive advanced lung cancer. Thoracic oncologist Michael Duruisseaux led the celebrations for both approvals with other HCPs retweeting his posts.

The three most shared links from HCPs discussing product launches in January were:

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.

 

Methodology

  • Using CREATION Pinpoint® the English-language Twitter conversations of HCPs globally discussing new pharmaceutical product launches and drug approvals between 1 January and 31 January 2022 were analysed in order to discover which new product launches HCPs are discussing as well as #WhatHCPsThink.
  • Mentions of drug approvals by the FDA, EMA, NICE, and CHMP were included in the data, as well as mentions of ‘drug approval’ by HCPs in their Twitter conversations.
  • Between 1 January and 31 January 2022, there were 4,166 HCP mentions of new pharmaceutical product launches and drug approvals from 2,797 unique HCP authors from around the world.

View the latest and archived product launch trackers here

View all articles >

CREATION Team photo of Research Associate Paul Cranston

Meet the Authors

Paul Cranston

Paul analyses the online conversations of HCPs to provide insights for pharmaceutical companies about what HCPs think. With a background in international development, he is passionate about using data to reveal the unmet needs in healthcare communities.

In his free time, Paul can often be found either writing songs on his guitar or kicking a ball around on a football field.

Tomi Shobande

Tomi is passionate about building relationships with clients and helping them attain their business goals and objectives. With a background in law, international development and human rights, she is keen on bringing about a positive difference around healthcare inequities and shaping health outcomes for all groups.

Tomi enjoys spending good quality time with friends and family. She also is passionate about travel and learning different cultures and histories along the way.

Suggested next


16.12.2020 | Article

#WhatHCPsthink about COVID-19’s impact on cancer diagnosis and treatment

The effect of COVID-19 on cancer diagnosis and treatment

By Lara Meyer

14.08.2017 | Case Study

Evidence for regulatory and payer submissions

Evidence for regulatory and payer submissions

View all articles >